Condition: Chronic Myelogenous Leukemia · Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive · Sponsor: Novartis Pharmaceuticals
The aim of this study is to support development of asciminib in the pediatric population (1 to \< 18 years) with Ph+ CML-CP. The study will evaluate the efficacy and safety of asciminib in pediatric formulation (weigh-based dose, fed state) or adult formulation (fasted) in newly diagnosed and resistant or intolerant Ph+ CML-CP with or without T315I mutation.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111
Always discuss trial participation with your own doctor first.
| Rutgers Cancer Institute of New Jersey | New Brunswick, New Jersey, United States | Recruiting |
| Columbia University Medical Center New York Presbyterian | New York, New York, United States | Recruiting |
| Seattle Childrens Hospital | Seattle, Washington, United States | Recruiting |
| Novartis Investigative Site | Brisbane, Queensland, Australia | Recruiting |
| Novartis Investigative Site | North Adelaide, South Australia, Australia | Recruiting |
| Novartis Investigative Site | Edmonton, Alberta, Canada | Recruiting |
| Novartis Investigative Site | Montreal, Quebec, Canada | Recruiting |
| Novartis Investigative Site | Zhengzhou, Henan, China | Recruiting |
| Novartis Investigative Site | Tianjin, China | Recruiting |
| Novartis Investigative Site | Marseille, France | Recruiting |
| Novartis Investigative Site | Paris, France | Recruiting |
| Novartis Investigative Site | Poitiers, France | Recruiting |
+ 12 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07354074